Relevant Publications

A small selection of some of the most relevant papers is included below to illustrate the potential of LSD1 as a therapeutic target in cancer.


1. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Harris WJ, Huang X, Lynch JT, Spencer GJ, Hitchin JR, Li Y, Ciceri F, Blaser JG, Greystoke BF, Jordan AM, Miller CJ, Ogilvie DJ, Somervaille TC. Cancer Cell. 2012 Apr 17;21(4):473-87. doi: 10.1016/j.ccr.2012.03.014.

2. Breaking the LSD1/KDM1A addiction: therapeutic targeting of the epigenetic modifier in AML. Lokken AA1, Zeleznik-Le NJ. Cancer Cell. 2012 Apr 17;21(4):451-3. doi: 10.1016/j.ccr.2012.03.027.

3. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Schenk T, Chen WC, Göllner S, Howell L, Jin L, Hebestreit K, Klein HU, Popescu AC, Burnett A, Mills K, Casero RA Jr, Marton L, Woster P, Minden MD, Dugas M, Wang JC, Dick JE, Müller-Tidow C, Petrie K, Zelent A. Nat Med. 2012 Mar 11;18(4):605-11. doi: 10.1038/nm.266.

4. Dynamic interaction between TAL1 oncoprotein and LSD1 regulates TAL1 function in hematopoiesis and leukemogenesis. Ying Li, Changwang Deng, Xin Hu, Bhavita Patel, Xueqi Fu, Yi Qiu, Marjorie Brand, Keji Zhao, Suming Huang. Oncogene. 2012 November 29; 31(48): 5007–5018. Published online 2012 February 6. doi: 10.1038/onc.2012.8.

5. Lysine-specific demethylase 1 (LSD1) is highly expressed in ER-negative breast cancers and a biomarker predicting aggressive biology. Lim S, Janzer A, Becker A, Zimmer A, Schule R, Buettner R, Kirfel J. Carcinogenesis. 2010;31:512–520.

6. NOTCH1 Nuclear Interactome Reveals Key Regulators of Its Transcriptional Activity and Oncogenic Function. Ahmad Yatim, Clarisse Benne, Bijan Sobhian, Sabine Laurent-Chabalier, Olivier Deas, Jean-Gabriel Judde, Jean-Daniel Lelievre, Yves Levy, Monsef Benkirane. Mol Cell. 2012 Nov 9;48(3):445-58. doi: 10.1016/j.molcel.2012.08.022. Epub 2012 Sep 27.